58.56
price down icon8.30%   -5.30
after-market アフターアワーズ: 58.40 -0.16 -0.27%
loading
前日終値:
$63.86
開ける:
$62.3
24時間の取引高:
2.07M
Relative Volume:
2.07
時価総額:
$1.98B
収益:
$55.23M
当期純損益:
$-164.08M
株価収益率:
-8.5538
EPS:
-6.8461
ネットキャッシュフロー:
$-208.68M
1週間 パフォーマンス:
-10.68%
1か月 パフォーマンス:
-32.27%
6か月 パフォーマンス:
+6.76%
1年 パフォーマンス:
+7,253%
1日の値動き範囲:
Value
$57.83
$63.00
1週間の範囲:
Value
$57.83
$66.80
52週間の値動き範囲:
Value
$0.6375
$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1107)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
63
Name
Twitter
@nektarnews
Name
次回の収益日
2026-05-07
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NKTR icon
NKTR
Nektar Therapeutics
58.56 2.16B 55.23M -164.08M -208.68M -6.8461
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
425.09 111.27B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
602.92 62.97B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
802.17 51.99B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
286.12 39.47B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
151.31 34.80B 742.00K -1.37B -1.07B -7.0731

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-24 開始されました Wedbush Neutral
2026-03-17 開始されました TD Cowen Buy
2026-02-10 アップグレード William Blair Mkt Perform → Outperform
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
Jun 02, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review

Jun 02, 2026
pulisher
Jun 01, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jun 01, 2026
pulisher
May 28, 2026

Drug developers outpace Nasdaq Bio, rezpeg data sends up Nektar - BioWorld News

May 28, 2026
pulisher
May 28, 2026

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York - The AI Journal

May 28, 2026
pulisher
May 27, 2026

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - AOL.com

May 27, 2026
pulisher
May 27, 2026

Nektar Therapeutics to webcast at 2026 Jefferies Global Healthcare Conference on June 3 - Pluang

May 27, 2026
pulisher
May 27, 2026

How to watch Nektar’s Jefferies healthcare fireside chat on June 3 - Stock Titan

May 27, 2026
pulisher
May 27, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out - ACCESS Newswire

May 27, 2026
pulisher
May 26, 2026

Interim CFO at Nektar Therapeutics (NKTR) files initial Form 3 ownership report - Stock Titan

May 26, 2026
pulisher
May 26, 2026

Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data (NKTR) - Seeking Alpha

May 26, 2026
pulisher
May 25, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire

May 25, 2026
pulisher
May 24, 2026

A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial - simplywall.st

May 24, 2026
pulisher
May 23, 2026

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - The Motley Fool

May 23, 2026
pulisher
May 22, 2026

Prosight Management Increases Stake in Nektar Therapeutics - Intellectia AI

May 22, 2026
pulisher
May 22, 2026

Nektar TherapeuticsCommon Stock (NQ: NKTR - The Chronicle-Journal

May 22, 2026
pulisher
May 22, 2026

NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill

May 22, 2026
pulisher
May 21, 2026

Nektar Therapeutics R&D chief sells $13,036 in shares - Investing.com UK

May 21, 2026
pulisher
May 21, 2026

Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares By Investing.com - Investing.com South Africa

May 21, 2026
pulisher
May 21, 2026

Nektar Therapeutics R&D chief sells $13,036 in shares By Investing.com - Investing.com South Africa

May 21, 2026
pulisher
May 21, 2026

Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares - Investing.com

May 21, 2026
pulisher
May 21, 2026

Nektar Therapeutics (NKTR) R&D chief sells shares to cover RSU tax - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Nektar Therapeutics (NKTR) CEO logs small 444-share tax-related stock sale - Stock Titan

May 21, 2026
pulisher
May 21, 2026

Is Nektar Therapeutics’ (NKTR) New CFO Hire and Equity Program Reframing Its Capital-Market Strategy? - simplywall.st

May 21, 2026
pulisher
May 20, 2026

Nektar Q1 earnings & revenues lag estimates, pipeline in focus - MSN

May 20, 2026
pulisher
May 20, 2026

Nektar Names Linda Rubinstein CFO As Funding And Dilution Questions Loom - simplywall.st

May 20, 2026
pulisher
May 19, 2026

[144] NEKTAR THERAPEUTICS SEC Filing - Stock Titan

May 19, 2026
pulisher
May 19, 2026

Why Nektar Therapeutics Stock Rocked it Today - MSN

May 19, 2026
pulisher
May 17, 2026

Nektar Therapeutics stock (US6354171056): FDA update and pipeline focus - AD HOC NEWS

May 17, 2026
pulisher
May 17, 2026

Patient Square Capital LP Acquires 210,000 Shares of Nektar Therapeutics in Q1 2026News and Statistics - IndexBox

May 17, 2026
pulisher
May 16, 2026

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares - AOL.com

May 16, 2026
pulisher
May 15, 2026

BVF Group (NKTR) reports up to 2.85M shares—9.8% aggregate holding - Stock Titan

May 15, 2026
pulisher
May 15, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 15, 2026
pulisher
May 15, 2026

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail

May 15, 2026
pulisher
May 14, 2026

Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - 富途牛牛

May 14, 2026
pulisher
May 14, 2026

Nektar Therapeutics stock (US6354171056): $400M capital raise fuels Phase 3 autoimmune pipeline - AD HOC NEWS

May 14, 2026
pulisher
May 13, 2026

Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery - simplywall.st

May 13, 2026
pulisher
May 12, 2026

Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum - Yahoo Finance

May 12, 2026
pulisher
May 12, 2026

Nektar Therapeutics Raises $374 Million After Alopecia Data Release; AnaptysBio’s First Tracks Bio Debuts on NASDAQ - geneonline.com

May 12, 2026
pulisher
May 11, 2026

Why Nektar Therapeutics Shares Are Sliding Now - TipRanks

May 11, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.25
price down icon 2.89%
$103.73
price down icon 2.17%
$89.14
price down icon 2.79%
$54.01
price down icon 2.12%
ONC ONC
$274.69
price down icon 1.78%
$151.31
price down icon 7.56%
大文字化:     |  ボリューム (24 時間):